Fortive to Present at the J.P. Morgan 2021 Industrials Conference

Fortive to Present at the J.P. Morgan 2021 Industrials Conference

EVERETT, Wash.–(BUSINESS WIRE)–
Fortive Corporation (“Fortive”) (NYSE: FTV) today announced that President and Chief Executive Officer, Jim Lico, and Senior Vice President and Chief Financial Officer, Chuck McLaughlin, will be presenting at the J.P. Morgan 2021 Industrials Conference on Monday, March 15, 2021 at 2:50 p.m. ET. The audio will be simultaneously webcast and will be archived on www.fortive.com.

ABOUT FORTIVE

Fortive is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. The company holds leading positions in intelligent operating solutions, precision technologies, and advanced healthcare solutions. Fortive is headquartered in Everett, Washington and employs a team of more than 17,000 research and development, manufacturing, sales, distribution, service and administrative employees in more than 50 countries around the world. With a culture rooted in continuous improvement, the core of our company’s operating model is the Fortive Business System. For more information please visit: www.fortive.com.

Griffin Whitney

Vice President, Investor Relations

Fortive Corporation

6920 Seaway Boulevard

Everett, WA 98203

Telephone: (425) 446-5000

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Software Technology Hardware Other Technology

MEDIA:

Logo
Logo

Alan WheatJoins Perdoceo Education Corporation Board of Directors

Alan WheatJoins Perdoceo Education Corporation Board of Directors

SCHAUMBURG, Ill.–(BUSINESS WIRE)–
Perdoceo Education Corporation (NASDAQ: PRDO), a provider of postsecondary education programs, today announced that Alan D. Wheat has been appointed to the Company’s Board of Directors. Mr. Wheat’s appointment follows a March 8, 2021 vote by the Board of Directors to expand the number of eligible board seats from eight to nine.

Former Congressman Alan Wheat currently serves as the chair of the Polsinelli law firm’s national Public Policy Practice. In 1982, he was elected to the United States House of Representatives, where he became part of the House leadership as the youngest member in Congressional history to be appointed to the powerful Rules Committee. While in Congress, he was one of the nation’s first African-Americans to represent a district with a white majority. Congressman Wheat left the House in 1994 to run for a seat in the United States Senate. He was the first minority candidate selected as a major party nominee for statewide office in Missouri. After his unsuccessful Senate race, Mr. Wheat accepted the position of vice president of Public Policy and Government Relations with CARE, one of the largest and most vital global relief and development organizations. After CARE, he served as Deputy Campaign Manager in the 1996 Clinton-Gore campaign and later formed Wheat Government Relations which he headed until joining Polsinelli in 2013. Mr. Wheat is the Chairman of Public Policy at Polsinelli where he continues to manage a bi-partisan team of public policy professionals.

“We are extremely pleased to have Alan Wheat join our board,” said Thomas Lally, Chairman of the Board of Directors. “With his extensive knowledge of the legislative and regulatory processes, Mr. Wheat will add invaluable experience and insight to our board.”

About Perdoceo Education Corporation

Perdoceo’s academic institutions offer a quality postsecondary education primarily online to a diverse student population, along with campus-based and blended learning programs. The Company’s accredited institutions – Colorado Technical University (“CTU”) and the American InterContinental University System (“AIU”) – provide degree programs through the master’s or doctoral level as well as associate and bachelor’s levels. Perdoceo’s universities offer students industry-relevant and career-focused degree programs that are designed to meet the educational needs of today’s busy adults. CTU and AIU continue to show innovation in higher education, advancing personalized learning technologies like their intellipath® learning platform and using data analytics and technology to support students and enhance learning. Perdoceo is committed to providing quality education that closes the gap between learners who seek to advance their careers and employers needing a qualified workforce.

Investors:

Alpha IR Group

Wyatt Turk or Chris Hodges

(312) 445-2870

[email protected]

Or

Media:

Perdoceo Education Corporation

(847) 585-2600

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Education Public Policy/Government Other Government Continuing Training University

MEDIA:

Logo
Logo

ImmunityBio and NantKwest Complete Merger

ImmunityBio and NantKwest Complete Merger

Creates Leading Immunotherapy and Cell Therapy Company

CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. (“ImmunityBio”) and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker “IBRX.”

“ImmunityBio is the culmination of a decades-long quest to orchestrate natural killer cells and T cells to induce what we call ‘immunogenic cell death’. By integrating novel immunotherapy molecules with a state-of-the-art natural killer cell therapy and viral vectors, we are now in the position to transform treatments for patients afflicted with cancer and infectious diseases by activating the host immune system,” said Patrick Soon-Shiong, M.D., Executive Chairman of the ImmunityBio Board. “With the merger complete, ImmunityBio has the scale that will allow us to advance our development of more novel therapies in oncology and infectious diseases, and accelerate work on our unique COVID-19 vaccine, which we believe is key to creating long-term immunity to the SARS-CoV-2 virus.”

“We are excited to bring together these innovative organizations and talented teams to create a leading immunotherapy and cell therapy company,” said Rich Adcock, Chief Executive Officer of ImmunityBio. “Together we expect to deliver important new treatments for patients, as we leverage our best-in-class platforms, expertise and resources to further accelerate our pipeline. We believe that our teams are prepared to seamlessly execute our go-forward strategy. We are excited to deliver on our mission on behalf of our shareholders, partners, and other stakeholders.”

Transaction Details

Pursuant to the merger, the former stockholders of ImmunityBio are entitled to receive 0.8190 of a share of NantKwest common stock for each outstanding share of ImmunityBio common stock that they held immediately prior to the merger. Former ImmunityBio stockholders should contact American Stock Transfer & Trust Company, LLC, the exchange agent for the transaction, by calling toll-free at (877) 248-6417 or at (718) 921-8317, if they have any questions regarding the consideration to which they are entitled.

About ImmunityBio

ImmunityBio, Inc. (NASDAQ: IBRX) is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.”

ImmunityBio’s platform is based on the foundation of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, second-generation human adenovirus (hAd5) and yeast vaccine technologies, and state-of-the-art, off-the-shelf natural killer cells, including autologous and allogenic cytokine-enhanced memory NK cells.

The company has an unparalleled immunotherapy clinical pipeline of over 40 clinical trials in Phase 1, 2, 3 development across 19 indications in solid and liquid cancers and infectious diseases. ImmunityBio has an expansive clinical-stage pipeline and intellectual property portfolio with 17 first-in-human antibody cytokine fusion proteins, chemo immuno-modulators, vaccine vectors, and cell therapies in 25 Phase II to III clinical trials. Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

ImmunityBio is the leading producer of cryopreserved and clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The company has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise, ready-to-scale facilities, extensive and seasoned R&D, clinical trial, and regulatory operations and development teams. For more information, please visit: www.immunitybio.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues”, “could”, “estimates,” “expects,” “intends,” “may,” “plans,” “potential”, “predicts”, “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction, (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger, (iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or ImmunityBio’s operations or operating expenses. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in NantKwest’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Investors

Sarah Singleton

ImmunityBio, Inc.

844-696-5235, Option 5

Media

Amy Jobe, Ph.D.

LifeSci Communications

315-879-8192

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Infectious Diseases Biotechnology Health Oncology

MEDIA:

Logo
Logo

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

– Dosed first patient in the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia –

– Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, including MT-401, for clinical activities and potential commercialization; facility expected to be fully operational in 1H 2021 –

PR Newswire

HOUSTON, March 9, 2021 /PRNewswire/ — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020.  

“We are proud of our Company’s continued progress, which has positioned us for a busy and productive year ahead,” said Peter L. Hoang, President & CEO of Marker Therapeutics. “Recently, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia (AML). In the fourth quarter, we completed construction of a new in-house cGMP manufacturing facility in Houston, which we anticipate will be fully operational in the first half of this year. We also continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration, superior T cell phenotype and antigen specificity, and the potential for improved patient outcomes.”

RECENT PROGRAM UPDATES


MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML

Phase 2 AML Trial

  • In March 2021, Marker dosed the first patient in the safety lead-in portion of its Phase 2 trial in AML. The safety lead-in is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and the remaining three to be treated with MT-401 manufactured with a new reagent from an alternate supplier.
  • To date, Marker has activated seven clinical sites and is in the start-up phase with additional clinical sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates activating a total of approximately 20 sites.

Manufacturing and Process Improvements

  • Marker continues to streamline and simplify the MT-401 manufacturing process. The technical improvements include a 50% reduction in manufacturing time, a 90%+ reduction in the number of required operator interventions, and significant improvement in the consistency and reproducibility of the manufacturing process, while yielding a significant increase in the number of T cells available for patient administration. The Company believes the new process could yield a measurably improved product, with superior T cell phenotype and antigen specificity as compared to the original process. The new process improvements have been updated in the CMC section of the IND and will be used for all patients in the Marker AML Phase 2 clinical trial.

BUSINESS UPDATES

  • The Company completed the construction and qualification of its cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport. The facility will allow production of MultiTAA-specific T cell products according to U.S. FDA guidelines and is designed to be scalable using modular processes. The facility will be used to support the manufacture of study drug for Marker’s Phase 2 AML trial (MT-401) and for future hematological and solid tumor trials, in addition to the potential commercialization of any approved products. The Company has initiated the technology transfer process and expects the facility to be fully operational in the first half of 2021.  

FISCAL YEAR 2020 FINANCIAL RESULTS

Cash Position and Guidance: At December 31, 2020, Marker had cash and cash equivalents of $21.4 million. The Company raised $6.2 million through the previously executed $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $23.8 million available to Marker from Aspire Capital, along with current cash available, funds operations into Q1 2022.

R&D Expenses: Research and development expenses were $18.9 million for the year ended December 31, 2020, compared to $12.8 million for the year ended December 31, 2019.

G&A Expenses: General and administrative expenses were $10.5 million for the year ended December 31, 2020, compared to $10.0 million for the year ended December 31, 2019.

Net Loss: Marker reported a net loss of $28.7 million for the year ended December 31, 2020, compared to a net loss of $21.4 million for the year ended December 31, 2019.  

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401, as well as clinical trials conducted by our collaborators; the timing and success of the technology transfer process related to our planned manufacturing facility and the receipt of regulatory approval for the related cGMP; our manufacturing processes and our ability to use our current and planned manufacturing facilities to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Consolidated Balance Sheets


December 31,


December 31,


2020


2019


ASSETS

Current assets:

Cash and cash equivalents

$           21,352,382

$        43,903,949

Prepaid expenses and deposits

2,057,924

1,526,442

Interest receivable

559

56,189

Other receivable

1,000,000

Total current assets

24,410,865

45,486,580

Non-current assets:

Property, plant and equipment, net

3,570,736

417,528

Construction in progress

6,789,098

Right-of-use assets, net

10,844,116

455,174

Total non-current assets

21,203,950

872,702


Total assets


$           45,614,815


$        46,359,282


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$             6,013,010

$          1,757,680

Lease liability

388,792

204,132

Warrant liability

31,000

Total current liabilities

6,401,802

1,992,812

Non-current liabilities:

Lease liability, net of current portion

11,868,440

280,247

Total non-current liabilities

11,868,440

280,247

Total liabilities

18,270,242

2,273,059

Commitments and contingencies

Stockholders’ equity:

Preferred stock – $0.001 par value, 5 million shares authorized and 0 shares issued and
outstanding at December 31, 2020 and 2019, respectively

Common stock, $0.001 par value, 150 million shares authorized, 50.7 million and 45.7
million shares issued and outstanding as of December 31, 2020 and 2019, respectively

50,731

45,728

Additional paid-in capital

383,533,326

371,573,909

Accumulated deficit 

(356,239,484)

(327,533,414)

Total stockholders’ equity

27,344,573

44,086,223


Total liabilities and stockholders’ equity


$           45,614,815


$        46,359,282

 


Marker Therapeutics, Inc.

Consolidated Statements of Operations


For the Years Ended


December 31,


2020


2019


Revenues:

Grant income

$                  466,785

$                  213,194

Total revenues

466,785

213,194


Operating expenses:

Research and development

18,880,751

12,764,804

General and administrative

10,471,846

9,977,196

Total operating expenses

29,352,597

22,742,000

Loss from operations

(28,885,812)

(22,528,806)


Other income (expense):

Change in fair value of warrant liabilities

31,000

18,000

Interest income

148,742

1,082,842


Net loss


$           (28,706,070)


$           (21,427,964)

Net loss per share, basic and diluted

$                      (0.61)

$                      (0.47)

Weighted average number of common shares outstanding

47,039,862

45,587,734

 


Marker Therapeutics, Inc.

Consolidated Statements of Cash Flows


For the Years Ended


December 31,


2020


2019


Cash Flows from Operating Activities:


Net loss

$           (28,706,070)

$        (21,427,964)


Reconciliation of net loss to net cash used in operating activities:

Depreciation and amortization

485,641

105,123

Changes in fair value of warrant liabilities

(31,000)

(18,000)

Stock-based compensation

5,228,409

5,356,972

Amortization on right-of-use assets

590,039

181,459


Changes in operating assets and liabilities:

Prepaid expenses and deposits

(531,482)

(1,384,725)

Interest receivable

55,630

51,988

Accounts payable and accrued expenses

4,222,470

(963,967)

Lease liability

(173,268)

(185,179)

Net cash used in operating activities

(18,859,631)

(18,284,293)


Cash Flows from Investing Activities:

Purchase of property and equipment

(3,638,849)

(374,983)

Purchase of construction in progress

(6,789,098)

Net cash used in investing activities

(10,427,947)

(374,983)


Cash Flows from Financing Activities:

Proceeds from issuance of common stock

6,186,011

Proceeds from exercise of stock options

57,744

Proceeds from exercise of warrants

550,000

758,733

Net cash provided by financing activities

6,736,011

816,477

Net decrease in cash

(22,551,567)

(17,842,799)

Cash and cash equivalents at beginning of the period

43,903,949

61,746,748


Cash and cash equivalents at end of the period

$             21,352,382

$          43,903,949

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-reports-fiscal-year-2020-operating-and-financial-results-301243927.html

SOURCE Marker Therapeutics, Inc.

Farmer Brothers Announces Participation at Roth’s 33rd Annual Investor Conference & Release Date for Investor Presentation

NORTHLAKE, Texas, March 09, 2021 (GLOBE NEWSWIRE) — Farmer Bros. Co. (NASDAQ: FARM) (the “Company”), a leading national coffee roaster, wholesaler, equipment servicer, and distributor of coffee, tea, and culinary products, today announced its attendance at Roth’s 33rd Annual Investor Conference on March 15th, 16th, and 17th.

The Company will be hosting virtual one-on-one meetings over the three days. In conjunction with the event, the Company will post an updated Investor Presentation on the Company’s website at www.farmerbros.com under “Investor Relations” on the morning of the 15th.

If you are attending the conference and would like to request a one-on-one meeting with management, please do so through the conference portal.

About Farmer Brothers

Founded in 1912, Farmer Bros. Co. is a national coffee roaster, wholesaler, equipment servicer, and distributor of coffee, tea, and culinary products. The Company’s product lines include organic, Direct Trade, and sustainably produced coffee. With a robust line of coffee, hot and iced teas, cappuccino mixes, spices, and baking/biscuit mixes, the Company delivers extensive beverage planning services and culinary products to its U.S.-based customers. The Company serves a wide variety of customers, from small independent restaurants and foodservice operators to large institutional buyers like restaurant, department and convenience store chains, hotels, casinos, healthcare facilities, and gourmet coffee houses, as well as grocery chains with private brand coffee and consumer branded coffee and tea products, and foodservice distributors.

Marketing Contact

Nathalie Oetzel
[email protected]

Investor Relations Contact

Ellipsis
Jeff Majtyka & Kyle King
[email protected]
(646) 776-0886



Qualtrics Reports Fourth Quarter and Full Year 2020 Financial Results

– Full Year 2020 Total Revenues of $763.5M, up 29% Year-over-year

– Q4 Total Revenues of $213.6M, up 24% Year-over-year

– Full Year 2020 Subscription Revenues of $575.4M, up 34% Year-over-year

– Q4 Subscription Revenues of $160.4M, up 33% Year-over-year

– Total Remaining Performance Obligations[1] of $1,144.4M, up 78% Year-over-year

– Next 12 Months Remaining Performance Obligations of $645.4M, up 49% Year-over-year

PR Newswire

SALT LAKE CITY and SEATTLE, March 9, 2021 /PRNewswire/ — Qualtrics (NASDAQ: XM), the leader in customer and employee experience and creator of the experience management category, today announced financial results for the fourth quarter and fiscal year ended December 31, 2020.

“With virtually everything moving to digital, Qualtrics’ mission to help companies design and continuously improve the experiences they deliver has never been more relevant, and that is reflected in our outstanding Q4 and 2020 results,” said Zig Serafin, CEO, Qualtrics. “We’re innovating faster than ever before to make our more than 13,500 customers successful, and we’re well positioned for continued strong growth in 2021.”

Fourth Quarter 2020 Financial Highlights:

  • Revenue: Total revenues for the fourth quarter were $213.6 million, up 24% year-over-year. Subscription revenues for the fourth quarter were $160.4 million, up from $120.5 million one year ago, an increase of 33% year-over-year.
  • Operating Loss and Margin: Fourth quarter operating loss was $11.0 million, compared to $145.0 million one year ago. Non-GAAP operating loss (see discussion of non-GAAP operating loss and margin measures below) was $4.7 million, compared to $18.5 million one year ago. For the fourth quarter, GAAP operating margin was (5)% and non-GAAP operating margin was (2)%.
  • Net Loss and Net Loss Per Share: Fourth quarter net loss was $14.5 million, or $(0.03) per share, compared to $147.3 million, or $(0.35) per share in the fourth quarter of fiscal year 2019. Non-GAAP net loss (see discussion of non-GAAP net loss measure below) for the fourth quarter was $8.1 million, or $(0.02) per share, compared to $20.3 million, or $(0.05) per share in the fourth quarter of fiscal year 2019.
  • Cash and Cash Equivalents: Total cash and cash equivalents as of December 31, 2020 was $203.9 million

Full Year 2020 Financial Highlights:

  • Revenue: Total revenues for the fiscal year ended December 31, 2020 were $763.5 million, up from $591.2 million one year ago, an increase of 29% year-over-year. Subscription revenues were $575.4 million, up from $430.0 million one year ago, an increase of 34% year-over-year.
  • Operating Loss and Margin: Operating loss for the year was $255.1 million, compared to operating loss of $994.1 million in 2019. Non-GAAP operating loss for the year was $29.6 million, compared to $49.5 million in fiscal 2019. For the fiscal year 2020, Operating margin was (33)% and non-GAAP operating margin was (4)%.
  • Net Loss and Net Loss Per Share: Fiscal year 2020 net loss was $272.5 million, or $(0.64) per share, compared to $1,007.6 million in fiscal year 2019, or $(1.76) per share from January 23, 2019 through December 31, 2019. Non-GAAP net loss for the year was $46.0 million, or $(0.11) per share, compared to $59.3 million in fiscal year 2019, or $(0.12) per share from January 23, 2019 through December 31, 2019.

[1] Remaining performance obligations represent all contracted future revenue that has not yet been recognized, including both deferred revenue and non-cancelable contracted amounts that will be invoiced and recognized as revenue in future periods.

Financial Outlook: 

Qualtrics is providing guidance for its first quarter ending March 31, 2021 as follows:

  • Subscription revenues between $176 and $178 million.
  • Total revenues between $226 and $228 million.
  • Non-GAAP operating margin between (1%) and (2%).
  • Non-GAAP net loss per share between $(0.02) and $(0.04) assuming 487 million weighted shares outstanding.

Qualtrics is providing guidance for its full year ending December 31, 2021 as follows:

  • Subscription revenues between $738 and $742 million.
  • Total revenues between $950 and $954 million.
  • Non-GAAP operating margin between (4%) and (5%).
  • Non-GAAP net loss per share between $(0.16) and $(0.18) assuming 513 million weighted shares outstanding.

The guidance provided above are forward-looking statements and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

Non-GAAP operating loss, non-GAAP operating margin, non-GAAP net loss and non-GAAP net loss per share are non-GAAP financial measures. Additional information on Qualtrics’ reported results, including a reconciliation of the non-GAAP financial measures to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Qualtrics’ results computed in accordance with GAAP.

A supplemental financial presentation and other information can be accessed through Qualtrics’ investor relations website at https://www.qualtrics.com/investors/.

Qualtrics Earnings Call
Qualtrics plans to host a conference call today to review its fiscal fourth quarter and full year 2020 financial results and to discuss its financial outlook. The call is scheduled to begin at 3:00 p.m. MT/5:00 p.m. ET. Investors are invited to join the webcast by visiting: https://qualtrics.com/investors/events. The webcast will be available live, and a replay will be available following completion of the live broadcast for approximately 90 days.

About Qualtrics
Qualtrics, the leader in customer experience and creator of the Experience Management (XM) category, is changing the way organizations manage and improve the four core experiences of business––customer, employee, product, and brand. Over 13,500 organizations around the world are using Qualtrics to listen, understand, and take action on experience data (X-data™)––the beliefs, emotions, and intentions that tell you why things are happening, and what to do about it. The Qualtrics XM Platform™ is a system of action that helps businesses attract customers who stay longer and buy more, engage employees who build a positive culture, develop breakthrough products people love, and build a brand people are passionate about. To learn more, please visit qualtrics.com.

Forward-Looking Statements
This press release contains express and implied “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook for the first quarter of 2021 and full year 2021, Qualtrics’ growth strategy and business aspirations, its market position, and the continued impact of COVID-19 on its business and operations. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” “target,” “explore,” “continue,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including: our future financial performance, including our revenue, cost of revenue, gross profit, operating expenses, ability to generate positive cash flow, and ability to be profitable; our ability to grow at or near historical growth rates; anticipated technology trends, such as the use of and demand for experience management software; our ability to attract and retain customers to use our products; our ability to respond to and overcome challenges brought by the COVID-19 pandemic; our ability to attract enterprises and international organizations as customers for our products; our ability to expand our network with content consulting partners, delivery partners, and technology partners; the evolution of technology affecting our products and markets; our ability to introduce new products and enhance existing products and to compete effectively with competitors; our ability to successfully enter into new markets and manage our international expansion; the attraction and retention of qualified employees and key personnel; our ability to effectively manage our growth and future expenses and maintain our corporate culture; our anticipated investments in sales and marketing, and research and development; our ability to maintain, protect, and enhance our intellectual property rights; our ability to successfully defend litigation brought against us; our ability to maintain data privacy and data security; the sufficiency of our cash and cash equivalents to meet our liquidity needs; our ability to comply with modified or new laws and regulations applying to our business; and our reduced ability to leverage resources at SAP as an independent company from SAP. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements will be included under the caption “Risk Factors” and elsewhere in Qualtrics’ Annual Report on Form 10-K that will be filed with the Securities and Exchange Commission and any subsequent public filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to Qualtrics at the time those statements are made and/or management’s good faith belief as of that time with respect to future events.  Qualtrics assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

Non-GAAP Financial Measures
To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core operating performance. These non-GAAP financial measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors’ overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We believe that these non-GAAP financial measures provide useful information about our financial performance, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to important metrics used by our management for financial and operational decision-making. We are presenting these non-GAAP measures to assist investors in seeing our financial performance using a management view, and because we believe that these measures provide an additional tool for investors to use in comparing our core financial performance over multiple periods with other companies in our industry. You should consider non-GAAP results alongside other financial performance measures and results presented in accordance with GAAP. In addition, in evaluating non-GAAP results, you should be aware that in the future we will incur expenses such as those that are the subject of adjustments in deriving non-GAAP results and you should not infer from our non-GAAP results that our future results will not be affected by these expenses or any unusual or non-recurring items.

Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating loss, non-GAAP operating margin, non-GAAP net loss, non-GAAP net loss per share, free cash flow, free cash flow margin: We define these non-GAAP financial measures as the respective GAAP measures, excluding equity and cash settled stock-based compensation expenses, amortization of acquired intangible assets, advisory and legal costs related to the SAP Acquisition, and the tax impact of the non-GAAP adjustments. When evaluating the performance of our business and making operating plans, we do not consider these items (for example, when considering the impact of equity award grants, we place a greater emphasis on overall stockholder dilution rather than the accounting charges associated with such grants). We believe it is useful to exclude these expenses in order to better understand the long-term performance of our core business and to facilitate comparison of our results to those of peer companies and over multiple periods.

Investor Relations:

Steven Wu

Head of FP&A and Investor Relations
[email protected]

Public Relations:

Gina Sheibley

Chief Communications Officer
[email protected]

 


Qualtrics International Inc.


Consolidated Balance Sheets


(Unaudited, in thousands, except share and par value)


As of December 31,


2020


2019

Assets

Current assets:

Cash and cash equivalents

$

203,891

$

42,467

Accounts receivable, net of allowance

296,148

193,692

Deferred contract acquisition costs, net

43,429

22,168

Prepaid expenses and other current assets

48,130

37,090

Total current assets

591,598

295,417

Non-current assets:

Property and equipment, net

116,120

51,067

Right-of-use assets from operating leases

195,372

184,838

Goodwill

6,709

6,709

Other intangible assets, net

3,959

5,414

Deferred contract acquisition costs, net of current portion

115,837

54,832

Deferred tax assets

92

3,313

Other assets

9,368

1,694

Total assets

$

1,039,055

$

603,284

Liabilities, redeemable convertible preferred stock, and deficit

Current liabilities:

Lease liabilities

$

7,125

$

7,893

Accounts payable

30,452

31,707

Accrued liabilities

225,046

80,029

Liability-classified, stock-based awards

209,286

286,991

Deferred revenue

495,638

382,602

Total current liabilities

967,547

789,222

Non-current liabilities:

Lease liabilities, net of current portion

235,620

182,274

Liability-classified, stock-based awards, net of current portion

76,627

161,237

Deferred revenue, net of current portion

5,477

4,182

Deferred tax liabilities

5,970

Other liabilities

16,716

6,889

Total liabilities

$

1,307,957

$

1,143,804

Commitments and contingencies

Equity (deficit)

Preferred stock, par value $0.0001 per share; authorized 100,000,000 shares; no shares outstanding

Class A common stock, par value $0.0001 per share; authorized 2,000,000,000 shares; issued and outstanding 6,000,000 and no shares as of December 31, 2020 and 2019

1

Class B common stock, par value $0.0001 per share; authorized 1,000,000,000 shares; issued and outstanding 423,170,610 and 423,170,610 as of December 31, 2020 and 2019

42

42

Additional paid in capital

1,126,631

586,631

Accumulated other comprehensive income (loss)

3,191

(928)

Accumulated deficit

(1,398,767)

(1,126,265)

Total deficit

(268,902)

(540,520)

Total liabilities, redeemable convertible preferred stock, and deficit

$

1,039,055

$

603,284

 

 


Qualtrics International Inc.


Consolidated Statements of Operations


(Unaudited, in thousands, except share data)


Three Months Ended December 31,


Year Ended December 31,


2020


2019


2020


2019

Revenue:

Subscription

$

160,397

$

120,476

$

575,397

$

430,038

Professional services and other

53,169

52,331

188,125

161,117

Total revenue

213,566

172,807

763,522

591,155

Cost of revenue:

Subscription

15,697

16,419

62,671

67,982

Professional services and other

35,756

36,817

135,816

117,509

Total cost of revenue

51,453

53,236

198,487

185,491

Gross profit

162,113

119,571

565,035

405,664

Operating expenses:

Research and development

43,810

58,658

212,795

242,124

Sales and marketing

109,019

112,871

431,794

440,325

General and administrative

20,274

93,021

175,499

717,363

Total operating expenses

173,103

264,550

820,088

1,399,812

Operating loss

(10,990)

(144,979)

(255,053)

(994,148)

Other non-operating income (expense), net

(489)

180

(972)

(486)

Loss before income taxes

(11,479)

(144,799)

(256,025)

(994,634)

Provision for income taxes

2,996

2,471

16,477

12,999

Net loss

$

(14,475)

$

(147,270)

$

(272,502)

$

(1,007,633)


Three Months
Ended D
ecember 31, 2020


Three Months
Ended
December 31, 2019


Year Ended
December 31, 2020


January 23, 2019
through
December 31, 2019

Net loss per share attributable to common stockholder, basic

$

(0.03)

$

(0.35)

$

(0.64)

$

(1.76)

Weighted-average Class A and Class B shares used in computing net loss per share attributable to common stockholder, basic

423,829,951

423,170,610

423,334,994

423,170,610

 

 


Qualtrics International Inc.


Consolidated Statements of Cash Flows


(Unaudited, in thousands)


Three Months Ended December 31,


Year Ended December 31,


2020


2019


2020


2019


Cash flows from operating activities

Net loss

$

(14,475)

$

(147,270)

$

(272,502)

$

(1,007,633)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation and amortization

7,887

5,661

26,457

19,715

Reduction of right-of-use assets from operating leases

4,773

4,088

17,202

9,031

Stock-based compensation expense, including cash settled

5,964

126,105

224,013

876,226

Amortization of deferred contract acquisition costs

9,715

5,642

32,098

19,513

Deferred income taxes

10,528

(1,921)

13,200

(5,321)

Changes in assets and liabilities:

Accounts receivable, net

(135,469)

(68,787)

(103,692)

(54,320)

Prepaid expenses and other current assets

(3,195)

(13,084)

(10,773)

(17,533)

Deferred contract acquisitions costs

(48,393)

(13,011)

(111,686)

(47,734)

Other assets

(1,214)

(190)

(7,592)

1,801

Lease liabilities

24,528

(2,307)

24,741

(6,375)

Accounts payable

(1,487)

6,537

(282)

7,219

Accrued liabilities

24,388

20,262

22,546

44,662

Deferred revenue

119,902

55,131

114,331

102,562

Other liabilities

2,701

(2,203)

9,826

55

Settlement of stock-based payments liabilities

(104,646)

(99,602)

(388,609)

(312,772)

Net cash flows used in operating activities

(98,493)

(124,949)

(410,722)

(370,904)


Cash flows from investing activities

Purchases of property and equipment

(46,464)

(6,712)

(89,518)

(33,181)

Net cash flows used in investing activities

(46,464)

(6,712)

(89,518)

(33,181)


Cash flows from financing activities

Proceeds from capital contributions from SAP

140,000

115,000

540,000

869,500

Proceeds from issuance of class A common stock

120,000

120,000

Settlement of equity-based awards

(539,707)

Net cash flows provided by financing activities

260,000

115,000

660,000

329,793

Effect of changes in exchange rates on cash and cash equivalents

1,348

152

1,664

1,316

Net increase (decrease) in cash and cash equivalents

116,391

(16,509)

161,424

(72,976)

Cash and cash equivalents at the beginning of the period

87,500

58,976

42,467

115,443

Cash and cash equivalents at the end of the period

$

203,891

$

42,467

$

203,891

$

42,467

 

 


Qualtrics International Inc.


Reconciliation of GAAP to Non-GAAP Measures


(Unaudited, in thousands)


Non-GAAP Gross Profit and Margin


Three Months Ended

December 31,


Year Ended

December 31,


2020


2019


2020


2019


(In thousands)

GAAP gross profit

$

162,113

$

119,571

$

565,035

$

405,664

Add: Stock-based compensation expense, including cash settled(1)

1,367

6,420

11,369

41,304

Add: Amortization of acquired intangible assets

265

282

1,062

1,160

Non-GAAP gross profit

$

163,745

$

126,273

$

577,466

$

448,128

Non-GAAP gross margin

77

%

73

%

76

%

76

%

We calculate non-GAAP gross profit as: GAAP gross profit excluding equity and cash settled stock-based compensation expense allocated to cost of revenue and amortization of acquired intangible assets allocated to cost of revenue. Non-GAAP gross margin is calculated as non-GAAP gross profit divided by total revenue.


Non-GAAP Operating Loss and Margin


Three Months Ended

December 31,


Year Ended

December 31,


2020


2019


2020


2019


(In thousands)

GAAP operating loss

$

(10,990)

$

(144,979)

$

(255,053)

$

(994,148)

Add: Stock-based compensation expense, including cash settled(1)

5,964

126,105

224,013

876,226

Add: Amortization of acquired intangible assets

363

360

1,454

1,478

Add: Advisory and legal costs related to the SAP Acquisition

66,992

Non-GAAP operating loss

$

(4,663)

$

(18,514)

$

(29,586)

$

(49,452)

Non-GAAP operating margin

(2)

%

(11)

%

(4)

%

(8)

%

We calculate non-GAAP operating loss as: GAAP operating loss excluding equity and cash settled stock-based compensation expense, amortization of acquired intangible assets, and advisory and legal costs related to the SAP Acquisition. Non-GAAP operating margin is calculated as non-GAAP operating loss divided by total revenue.

 


Non-GAAP Net Loss and Net Loss Per Share


Three Months Ended

December 31,


Year Ended

December 31,


2020


2019


2020


2019


(In thousands)

GAAP net loss

$

(14,475)

$

(147,270)

$

(272,502)

$

(1,007,633)

Add: Stock-based compensation expense, including cash settled(1)

5,964

126,105

224,013

876,226

Add: Amortization of acquired intangible assets

363

360

1,454

1,478

Add: Advisory and legal costs related to the SAP Acquisition

66,992

Add: Tax impact of the non-GAAP adjustments

29

530

1,075

3,684

Non-GAAP net loss

$

(8,119)

$

(20,275)

$

(45,960)

$

(59,253)


Three Months
Ended
December 31, 2020


Three Months
Ended
December 31, 2019


Year Ended
December 31, 2020


January 23, 2019
through
December 31, 2019

Weighted-average Class A and Class B shares used in computing non-GAAP net loss per share attributable to common stockholder, basic

423,829,951

423,170,610

423,334,994

423,170,610

Non-GAAP net loss per share attributable to common stockholder, basic

$

(0.02)

$

(0.05)

$

(0.11)

$

(0.12)

We calculate non-GAAP net loss as: GAAP net loss excluding equity and cash settled stock-based compensation expense, amortization of acquired intangible assets, advisory and legal costs related to the SAP Acquisition, and the tax impact of the non-GAAP adjustments. Non-GAAP net loss per share is calculated as non-GAAP net loss divided by the weighted-average Class A and Class B shares attributable to common stockholders. Due to the impact of the SAP acquisition of Qualtrics, the Company’s capital structure for the years ended December 31, 2020 and 2019 are not comparable. As a result, the presentation of net loss per share for the period prior to the SAP acquisition is not meaningful and only net loss per share for periods subsequent to the SAP acquisition of Qualtrics are presented.


Free Cash Flow and Margin


Three Months Ended

December 31,


Year Ended

December 31,


2020


2019


2020


2019


(In thousands)

Net cash used in operating activities

$

(98,493)

$

(124,949)

$

(410,722)

$

(370,904)

Less: Capital expenditures

(46,464)

(6,712)

(89,518)

(33,181)

Free cash flow

(144,957)

(131,661)

(500,240)

(404,085)

Free cash flow margin

(68)

%

(76)

%

(66)

%

(68)

%

As a result of the SAP Acquisition, we incurred significant cash outflows in connection with the settlement of liability-classified, stock-based awards in accordance with SAP’s employee equity compensation programs. We calculate free cash flow as net cash provided by operating activities less capital expenditures. Our free cash flow for the three months ended December 31, 2020 and 2019 and for the year ended December 31, 2020 and 2019 includes $104.6 million, $99.6 million, $388.6 million and $379.8 million, respectively, in cash outflows related to the settlement of liability-classified, stock-based awards and advisory and legal costs related to the SAP Acquisition. Free cash flow margin is calculated as free cash flow divided by total revenue.

________________


(1) 
As a result of the SAP Acquisition, our stock-based compensation expense reflects the recognition of both equity-classified awards and liability-classified awards. Liability-classified awards are settled in cash in accordance with SAP’s employee equity compensation programs. Liability-classified awards are recorded according to mark-to-market accounting.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/qualtrics-reports-fourth-quarter-and-full-year-2020-financial-results-301243919.html

SOURCE Qualtrics

IAC Monthly Metrics Available on Company’s IR Site

PR Newswire

NEW YORK, March 9, 2021 /PRNewswire/ — IAC (NASDAQ: IAC) posted monthly metrics for February 2021 on the investor relations section of its website at https://ir.iac.com/.

About IAC
IAC builds companies.  We are guided by curiosity, a questioning of the status quo, and a desire to invent or acquire new products and brands.  From the single seed that started as IAC over two decades ago have emerged 10 public companies and generations of exceptional leaders.  We will always evolve, but our basic principles of financially-disciplined opportunism will never change.  IAC today operates Vimeo, Dotdash and Care.com, among many others, and has majority ownership of ANGI Homeservices, which includes HomeAdvisor, Angie’s List and Handy.  The Company is headquartered in New York City and has business operations and satellite offices worldwide.

Cision View original content:http://www.prnewswire.com/news-releases/iac-monthly-metrics-available-on-companys-ir-site-301243898.html

SOURCE IAC

ANGI Monthly Metrics Available on IAC IR Site

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) — IAC (NASDAQ: IAC) posted monthly metrics for February 2021, including metrics for ANGI Homeservices Inc. (NASDAQ: ANGI), on the investor relations section of the IAC website at https://ir.iac.com/.

About ANGI Homeservices Inc.

ANGI Homeservices Inc. (NASDAQ: ANGI) turns home improvement jobs imagined into jobs well-done. People throughout North America and Europe rely on us to book quality home service pros across 500 different categories, from repairing and remodeling to cleaning and landscaping. Nearly 250,000 domestic service professionals actively seek consumer matches, complete jobs or advertise through ANGI Homeservices’ platforms and consumers turned to at least one of our brands to find a pro for more than 30 million projects last year. We’ve established category-transforming products through brands such as HomeAdvisor®, Angie’s List® and Handy – as well as international brands such as HomeStars, MyHammer, MyBuilder, Instapro, Travaux and Werkspot. Our marketplaces have enabled more than 150 million consumer-to-pro connections, meaningfully redefining how easily and effectively home pros are discovered and hired.  The Company is headquartered in Denver, Colorado. Learn more at www.angihomeservices.com

About IAC

IAC builds companies. We are guided by curiosity, a questioning of the status quo, and a desire to invent or acquire new products and brands. From the single seed that started as IAC over two decades ago have emerged 10 public companies and generations of exceptional leaders. We will always evolve, but our basic principles of financially-disciplined opportunism will never change. IAC today operates Vimeo, Dotdash and Care.com, among many others, and has majority ownership of ANGI Homeservices, which includes HomeAdvisor, Angie’s List and Handy. The Company is headquartered in New York City and has business operations and satellite offices worldwide.

Contacts:

IAC/ANGI Homeservices Investor Relations

Mark Schneider
(212) 314-7400

ANGI Homeservices Corporate Communications

Mallory Micetich
(303) 963-8352

IAC Corporate Communications

Valerie Combs
(212) 314-7361
(212) 314-7361



Impac Mortgage Holdings, Inc. Announces Upcoming Release of Year End 2020 Results and Conference Call

Impac Mortgage Holdings, Inc. Announces Upcoming Release of Year End 2020 Results and Conference Call

IRVINE, Calif.–(BUSINESS WIRE)–
Impac Mortgage Holdings, Inc. (NYSE American: IMH) (the Company), announces the scheduling of a conference call and live webcast on Thursday, March 11, 2021, at 2:00 p.m. P.T. (5:00 p.m. E.T.). We will discuss our year end 2020 financial results, which are expected to be released after the close of market on Thursday, March 11, 2021.

Conference Call

After the Company’s prepared remarks, management will host a live Q&A session to discuss the Company’s financial results and business outlook. To submit questions via email, please email your questions to [email protected].

To participate in the call, please dial in, up to fifteen minutes prior to the scheduled start time. You may access the call via:

The dial-in number is (844) 265-1560, conference ID number: 6551116

Internet Webcast Access: http://ir.impaccompanies.com or go to http://www.impaccompanies.com and link to Investor Relations.

The conference call will be archived approximately 2 hours following the call on the Impac Mortgage Holdings, Inc. web site at http://ir.impaccompanies.com/.

About the Company

Impac Mortgage Holdings, Inc. (IMH or Impac) provides innovative mortgage lending and real estate solutions that address the challenges of today’s economic environment. Impac’s operations include mortgage lending, servicing, portfolio loss mitigation and real estate services as well as the management of the securitized long-term mortgage portfolio, which includes the residual interests in securitizations.

For additional information, questions or comments, please call Justin Moisio, Chief Administrative Officer at (949) 475-3988 or email [email protected]. Web site: http://ir.impaccompanies.comor www.impaccompanies.com

Justin Moisio

Chief Administrative Officer

(949) 475-3988

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Finance Construction & Property Banking

MEDIA:

Logo
Logo

AeroVironment, Inc. Announces Fiscal 2021 Third Quarter Results

AeroVironment, Inc. Announces Fiscal 2021 Third Quarter Results

SIMI VALLEY, Calif.–(BUSINESS WIRE)–AeroVironment, Inc. (NASDAQ: AVAV), a global leader in unmanned aircraft systems (UAS), today reported financial results for its third quarter ended January 30, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005954/en/

AeroVironment's Portfolio of Unmanned Systems (Graphic: Business Wire)

AeroVironment’s Portfolio of Unmanned Systems (Graphic: Business Wire)

  • Revenue of $78.8 million, a year-over-year increase of 27 percent
  • Gross margin of $28.6 million, a year-over-year increase of 22 percent
  • Diluted earnings per share of $0.01, a year-over-year increase of $0.05
  • Diluted non-GAAP earnings per share of $0.14, a year-over-year increase of $0.15

“Our team delivered year-over-year increases in revenue, gross margin, diluted earnings per share and Non-GAAP diluted earnings per share in the third quarter, despite the ongoing challenges presented by the COVID-19 pandemic,” said Wahid Nawabi, AeroVironment president and chief executive officer. “We continue to shape our portfolio with three transformative acquisitions that we are confident will accelerate our success and value creation. Our acquisition of Arcturus UAV extends our reach and expands our solutions portfolio with medium UAS, which addresses a more than $1 billion segment of the UAS market. Our pending acquisition of Telerob will add a suite of unmanned ground vehicles to our portfolio, expanding our offering to the ground domain for defense and non-defense customers, such as law enforcement and first responders. Through our acquisition of Progeny Systems Corporation’s Intelligent Systems Group, we will accelerate AeroVironment’s development and deployment of critical technologies, such as artificial intelligence and perceptive autonomy, which will help our customers operate more effectively in contested airspace against peer and near-peer adversaries and increase our customer-funded research and development revenue.

“We continue to build on our momentum and recently received United States government approval for our first export of Switchblade 300 to an allied nation. We are delivering on our commitments while working toward achieving our fiscal year 2021 objectives to produce a fourth consecutive year of profitable, double-digit topline growth.”

FISCAL 2021 THIRD QUARTER RESULTS

Revenue for the third quarter of fiscal 2021 was $78.8 million, an increase of 27% from the third quarter of fiscal 2020 revenue of $61.9 million. The increase in revenue was due to an increase in product sales of $21.9 million, partially offset by a decrease in service revenue of $5.0 million.

Gross margin for the third quarter of fiscal 2021 was $28.6 million, an increase of 22% from the third quarter of fiscal 2020 gross margin of $23.5 million. The increase in gross margin was primarily due to an increase in product margin of $7.2 million, partially offset by a decrease in service margin of $2.1 million. As a percentage of revenue, gross margin decreased to 36% from 38%. The decrease in gross margin percentage was primarily due to an unfavorable product mix.

Loss from operations for the third quarter of fiscal 2021 was $0.6 million, a decrease of $0.5 million from the third quarter of fiscal 2020 loss from operations of $1.1 million. The decrease in loss from operations was primarily a result of an increase in gross margin of $5.2 million, partially offset by an increase in selling, general and administrative (“SG&A”) expense of $2.4 million, and an increase in research and development (“R&D”) expense of $2.3 million. The increase in SG&A expense for the third quarter of fiscal 2021 includes an increase in acquisition-related expenses of $3.1 million related to the acquisitions of Arcturus UAV and Progeny Systems Corporation’s Intelligent Systems Group (“ISG”) and the pending acquisition of Telerob GmbH.

Other income, net, for the third quarter of fiscal 2021 was $0.1 million, as compared to $1.2 million for the third quarter of fiscal 2020. The decrease in other income, net was primarily due to a decrease in interest income resulting from a decrease in the average interest rate earned on our investment portfolio.

Benefit from income taxes for the third quarter of fiscal 2021 was $0.9 million, as compared to $38 thousand for the third quarter of fiscal 2020. The increase in benefit from income taxes was primarily due to a decrease in the projected fiscal year 2021 effective tax rate.

Equity method investment loss, net of tax, for the third quarter of fiscal 2021 was $0.1 million, as compared to $1.2 million for the third quarter of fiscal 2020.

Net income attributable to AeroVironment for the third quarter of fiscal 2021 was $0.2 million, as compared to a net loss attributable to AeroVironment of $1.0 million for the third quarter of fiscal 2020.

Earnings per diluted share attributable to AeroVironment for the third quarter of fiscal 2021 was $0.01, as compared to a loss per diluted share attributable to AeroVironment of $0.04 for the third quarter of fiscal 2020.

Non-GAAP earnings per diluted share was $0.14 for the third quarter of fiscal 2021, as compared to a loss of $0.01 for the third quarter of fiscal 2020.

FISCAL 2021 YEAR-TO-DATE RESULTS

Revenue for the first nine months of fiscal 2021 was $258.9 million, an increase of 12% from the first nine months of fiscal 2020 revenue of $232.1 million. The increase in revenue was due to an increase in product sales of $22.6 million and an increase in service revenue of $4.2 million.

Gross margin for the first nine months of fiscal 2021 was $104.9 million, an increase of 5% from the first nine months of fiscal 2020 gross margin of $99.9 million. The increase in gross margin was primarily due to an increase in product margin of $2.8 million and an increase in service margin of $2.2 million. As a percentage of revenue, gross margin decreased to 41% from 43%. The decrease in gross margin percentage was primarily due to an unfavorable product mix.

Income from operations for the first nine months of fiscal 2021 was $25.6 million, a decrease of $0.2 million from the first nine months of fiscal 2020 of $25.8 million. The decrease in income from operations was primarily a result of an increase in R&D expense of $5.8 million, partially offset by an increase in gross margin of $5.0 million and a decrease in SG&A expense of $0.5 million. SG&A expense for the first nine months of fiscal 2021 includes an increase in acquisition-related expenses of $3.1 million related to the acquisitions of Arcturus UAV and ISG and the pending acquisition of Telerob.

Other income, net, for the first nine months of fiscal 2021 was $0.5 million, as compared to $4.3 million for the first nine months of fiscal 2020. The decrease in other income, net was primarily due to a decrease in interest income resulting from a decrease in the average interest rate earned on our investment portfolio.

Provision for income taxes for the first nine months of fiscal 2021 was $2.8 million, as compared to $3.2 million for the first nine months of fiscal 2020. The decrease in provision for income taxes was primarily due to a decrease in income before income taxes.

Equity method investment loss, net of tax, for the first nine months of fiscal 2021 was $10.9 million, as compared to $3.4 million for the first nine months of fiscal 2020. Equity method investment loss, net of tax, for the first nine months of fiscal 2021 included a loss of $8.4 million for our proportionate share of the HAPSMobile Inc. joint venture’s impairment of its investment in Loon LLC.

Net income attributable to AeroVironment for the first nine months of fiscal 2021 was $12.4 million, a decrease from the first nine months of fiscal 2020 net income attributable to AeroVironment of $23.6 million. The first nine months of fiscal 2021 included the impairment loss of $8.4 million related to HAPSMobile Inc.’s investment in Loon LLC.

Earnings per diluted share attributable to AeroVironment for the first nine months of fiscal 2021 was $0.51, as compared to the first nine months of fiscal 2020 of $0.98. The first nine months of fiscal 2021 included the impairment loss of $8.4 million related to HAPSMobile Inc.’s investment in Loon LLC.

Non-GAAP earnings per diluted share was $1.06 for the first nine months of fiscal 2021, as compared to $1.07 for the first nine months of fiscal 2020.

BACKLOG

As of January 30, 2021, funded backlog (remaining performance obligations under firm orders for which funding is currently appropriated to us under a customer contract) was $103.9 million, as compared to $208.1 million as of April 30, 2020.

FISCAL 2021 — OUTLOOK FOR THE FULL YEAR

For fiscal 2021, the Company narrows its revenue expectations to between $400 million and $410 million, representing the upper half of its prior range. The Company now expects net income of $18 million to $23 million, adjusted EBITDA of $64 million to $69 million and revised earnings per diluted share of $0.76 to $0.96. The revised earnings per diluted share outlook reflects reductions of $0.35 per diluted share for the HAPSMobile Inc. JV impairment of its investment in Loon LLC and $0.53 per diluted share for additional acquisition-related expenses and amortization of intangible assets. The Company continues to expect non-GAAP earnings per diluted share, which excludes the HAPSMobile Inc. impairment of its investment in Loon LLC, amortization of acquired intangible assets and acquisition-related expenses, of between $1.74 and $1.94. This outlook includes the impact of the two recently closed acquisitions in the fourth quarter of fiscal year 2021 and the anticipated closing of the third acquisition in the fourth quarter of fiscal year 2021.

As a result of the significant portfolio-shaping the Company has undertaken to position it for continued growth and success, consisting of the noted acquisitions, the Company is providing a preliminary outlook for the next fiscal year. For fiscal year 2022 the Company expects revenue of between $560 million and $580 million, net income of between $35 million and $40 million, adjusted EBITDA of between $110 million and $115 million, earnings per diluted share of between $1.38 and $1.58 and non-GAAP earnings per diluted share, which excludes acquisition-related expenses and amortization of intangible assets, of between $2.50 and $2.70. This preliminary outlook assumes the closing of the third acquisition in the fourth quarter of fiscal year 2021 and includes estimates of intangible asset amortization, which are subject to final purchase accounting. More refined expectations for fiscal year 2022 may be provided in the Company’s fourth quarter and full fiscal year 2021 earnings release.

The foregoing estimates are forward-looking and reflect management’s view of current and future market conditions, subject to certain risks and uncertainties, and including certain assumptions with respect to our ability to efficiently and on a timely basis integrate our acquisitions, obtain and retain government contracts, changes in the timing and/or amount of government spending, changes in the demand for our products and services, activities of competitors, changes in the regulatory environment, and general economic and business conditions in the United States and elsewhere in the world. Investors are reminded that actual results may differ materially from these estimates.

CONFERENCE CALL AND PRESENTATION

In conjunction with this release, AeroVironment, Inc. will host a conference call today, Tuesday, March 9, 2021, at 1:30 pm Pacific Time that will be webcast live. Wahid Nawabi, president and chief executive officer, Kevin P. McDonnell, chief financial officer and Steven A. Gitlin, chief marketing officer and vice president of investor relations, will host the call.

4:30 PM ET

3:30 PM CT

2:30 PM MT

1:30 PM PT

Investors may dial into the call by using the following telephone numbers, (877) 561-2749 (U.S.) or (678) 809-1029 (international) and providing the conference ID 9179576 five to ten minutes prior to the start time to allow for registration.

Investors with Internet access may listen to the live audio webcast via the Investor Relations page of the AeroVironment, Inc. website, http://investor.avinc.com. Please allow 15 minutes prior to the call to download and install any necessary audio software.

A supplementary investor presentation for the third fiscal quarter 2021 can be accessed at https://investor.avinc.com/events-and-presentations.

Audio Replay Options

An audio replay of the event will be archived on the Investor Relations page of the company’s website, at http://investor.avinc.com. The audio replay will also be available via telephone from Tuesday, March 9, 2021, at approximately 4:30 p.m. Pacific Time through March 16, 2021, at 4:30 p.m. Pacific Time. Dial (855) 859-2056 (U.S.) or (404) 537-3406 (international) and provide the conference ID 9179576.

ABOUT AEROVIRONMENT, INC.

AeroVironment (NASDAQ: AVAV) provides technology solutions at the intersection of robotics, sensors, software analytics and connectivity that deliver more actionable intelligence so you can Proceed with Certainty. Celebrating 50 years of innovation, AeroVironment is a global leader in unmanned aircraft systems and tactical missile systems, and serves defense, government and commercial customers. For more information, visit www.avinc.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “project,” “plan,” or words or phrases with similar meaning. Forward-looking statements are based on current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from the forward-looking statements.

Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, our ability to successfully consummate the transactions contemplated by the agreement to purchase Telerob on a timely basis, if at all, including the satisfaction of the closing conditions of such transaction; the impact of our recent acquisitions of Arcturus UAV and ISG and our ability to successfully integrate them into our operations; the risk that disruptions will occur from the transactions that will harm our business; any disruptions or threatened disruptions to our relationships with our distributors, suppliers, customers and employees; the ability to timely and sufficiently integrate international operations into our ongoing business and compliance programs; reliance on sales to the U.S. government; availability of U.S. government funding for defense procurement and R&D programs; changes in the timing and/or amount of government spending; our ability to perform under existing contracts and obtain new contracts; risks related to our international business, including compliance with export control laws; potential need for changes in our long-term strategy in response to future developments; the extensive regulatory requirements governing our contracts with the U.S. Government and international customers; the consequences to our financial position, business and reputation that could result from failing to comply with such regulatory requirements; unexpected technical and marketing difficulties inherent in major research and product development efforts; the impact of potential security and cyber threats; changes in the supply and/or demand and/or prices for our products and services; the activities of competitors and increased competition; failure of the markets in which we operate to grow; uncertainty in the customer adoption rate of commercial use unmanned aircraft systems; failure to remain a market innovator and create new market opportunities; changes in significant operating expenses, including components and raw materials; failure to develop new products; the extensive regulatory requirements governing our contracts with the U.S. government; risk of litigation, including but not limited to pending litigation arising from the sale of our EES business; product liability, infringement and other claims; changes in the regulatory environment; the impact of the outbreak related to the strain of coronavirus known as COVID-19 on our business operations; and general economic and business conditions in the United States and elsewhere in the world. For a further list and description of such risks and uncertainties, see the reports we file with the Securities and Exchange Commission. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

NON-GAAP MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. See in the financial tables below the calculation of these measures, the reasons why we believe these measures provide useful information to investors, and a reconciliation of these measures to the most directly comparable GAAP measures.

– Financial Tables Follow –

AeroVironment, Inc.

Consolidated Statements of Operations (Unaudited)

(In thousands except share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

January 30,

 

January 25,

 

January 30,

 

January 25,

 

 

2021

 

2020

 

2021

 

2020

Revenue:

 

 

 

 

 

 

 

 

 

Product sales

 

$

58,348

 

$

36,432

 

$

182,233

 

$

159,657

 

Contract services

 

 

20,434

 

 

25,459

 

 

76,664

 

 

72,416

 

 

 

 

78,782

 

 

61,891

 

 

258,897

 

 

232,073

 

Cost of sales:

 

 

 

 

 

 

 

 

 

Product sales

 

 

35,746

 

 

21,034

 

 

102,039

 

 

82,244

 

Contract services

 

 

14,395

 

 

17,361

 

 

51,955

 

 

49,895

 

 

 

 

50,141

 

 

38,395

 

 

153,994

 

 

132,139

 

Gross margin:

 

 

 

 

 

 

 

 

 

Product sales

 

 

22,602

 

 

15,398

 

 

80,194

 

 

77,413

 

Contract services

 

 

6,039

 

 

8,098

 

 

24,709

 

 

22,521

 

 

 

 

28,641

 

 

23,496

 

 

104,903

 

 

99,934

 

Selling, general and administrative

 

 

15,652

 

 

13,223

 

 

42,640

 

 

43,146

 

Research and development

 

 

13,631

 

 

11,381

 

 

36,710

 

 

30,948

 

(Loss) income from operations

 

 

(642

)

 

(1,108

)

 

25,553

 

 

25,840

 

Other income:

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

94

 

 

1,122

 

 

417

 

 

3,717

 

Other (expense) income, net

 

 

(37

)

 

120

 

 

68

 

 

632

 

(Loss) income before income taxes

 

 

(585

)

 

134

 

 

26,038

 

 

30,189

 

(Benefit from) provision for income taxes

 

 

(924

)

 

(38

)

 

2,774

 

 

3,203

 

Equity method investment loss, net of tax

 

 

(81

)

 

(1,200

)

 

(10,891

)

 

(3,410

)

Net income (loss)

 

 

258

 

 

(1,028

)

 

12,373

 

 

23,576

 

Net (income) loss attributable to noncontrolling interest

 

 

(47

)

 

20

 

 

12

 

 

27

 

Net income (loss) attributable to AeroVironment, Inc.

 

$

211

 

$

(1,008

)

$

12,385

 

$

23,603

 

Net income (loss) per share attributable to AeroVironment, Inc.

 

 

 

 

 

 

 

 

 

Basic

 

$

0.01

 

$

(0.04

)

$

0.52

 

$

0.99

 

Diluted

 

$

0.01

 

$

(0.04

)

$

0.51

 

$

0.98

 

Weighted-average shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

 

23,942,782

 

 

23,821,145

 

 

23,924,017

 

 

23,790,788

 

Diluted

 

 

24,260,874

 

 

23,821,145

 

 

24,216,371

 

 

24,076,195

 

AeroVironment, Inc.

Consolidated Balance Sheets

(In thousands except share data)

 

 

 

 

 

 

 

 

 

January 30,

 

April 30,

 

 

2021

 

2020

 

 

(Unaudited)

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

324,543

 

 

$

255,142

Short-term investments

 

 

48,499

 

 

 

47,507

Accounts receivable, net of allowance for doubtful accounts of $565 at January 30, 2021 and $1,190 at April 30, 2020

 

 

26,621

 

 

 

73,660

Unbilled receivables and retentions

 

 

61,084

 

 

 

75,837

Inventories

 

 

53,104

 

 

 

45,535

Prepaid expenses and other current assets

 

 

7,693

 

 

 

6,246

Total current assets

 

 

521,544

 

 

 

503,927

Long-term investments

 

 

11,222

 

 

 

15,030

Property and equipment, net

 

 

22,920

 

 

 

21,694

Operating lease right-of-use assets

 

 

11,281

 

 

 

8,793

Deferred income taxes

 

 

5,821

 

 

 

4,928

Intangibles, net

 

 

11,552

 

 

 

13,637

Goodwill

 

 

6,340

 

 

 

6,340

Other assets

 

 

312

 

 

 

10,605

Total assets

 

$

590,992

 

 

$

584,954

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

15,837

 

 

$

19,859

Wages and related accruals

 

 

20,081

 

 

 

23,972

Customer advances

 

 

4,279

 

 

 

7,899

Current operating lease liabilities

 

 

4,403

 

 

 

3,380

Income taxes payable

 

 

2,370

 

 

 

1,065

Other current liabilities

 

 

9,158

 

 

 

10,778

Total current liabilities

 

 

56,128

 

 

 

66,953

Non-current operating lease liabilities

 

 

8,426

 

 

 

6,833

Other non-current liabilities

 

 

243

 

 

 

250

Liability for uncertain tax positions

 

 

1,017

 

 

 

1,017

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value:

 

 

 

 

 

 

Authorized shares—10,000,000; none issued or outstanding at January 30, 2021 and April 30, 2020

 

 

 

 

 

Common stock, $0.0001 par value:

 

 

 

 

 

 

Authorized shares—100,000,000

 

 

 

 

 

 

Issued and outstanding shares—24,102,691 shares at January 30, 2021 and 24,063,639 shares at April 30, 2020

 

 

2

 

 

 

2

Additional paid-in capital

 

 

184,366

 

 

 

181,481

Accumulated other comprehensive income

 

 

347

 

 

 

328

Retained earnings

 

 

340,475

 

 

 

328,090

Total AeroVironment, Inc. stockholders’ equity

 

 

525,190

 

 

 

509,901

Noncontrolling interest

 

 

(12

)

 

 

Total equity

 

 

525,178

 

 

 

509,901

Total liabilities and stockholders’ equity

 

$

590,992

 

 

$

584,954

AeroVironment, Inc.

Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

January 30,

 

January 25,

 

 

2021

 

2020

Operating activities

 

 

 

 

Net income

 

$

12,373

 

$

23,576

 

Adjustments to reconcile net income to cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

 

8,650

 

 

7,107

 

Losses from equity method investments

 

 

10,891

 

 

3,410

 

Realized gain from sale of available-for-sale investments

 

 

(11

)

 

 

Provision for doubtful accounts

 

 

(145

)

 

(2

)

Other non-cash income

 

 

(473

)

 

(719

)

Non-cash lease expense

 

 

3,592

 

 

3,453

 

Loss on foreign currency transactions

 

 

1

 

 

 

Deferred income taxes

 

 

(897

)

 

(946

)

Stock-based compensation

 

 

4,754

 

 

4,751

 

Loss (gain) on sale of property and equipment

 

 

2

 

 

(71

)

Amortization of debt securities

 

 

143

 

 

(1,291

)

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

 

 

Accounts receivable

 

 

47,184

 

 

3,245

 

Unbilled receivables and retentions

 

 

14,753

 

 

(24,364

)

Inventories

 

 

(7,569

)

 

(10,766

)

Income tax receivable

 

 

 

 

821

 

Prepaid expenses and other assets

 

 

(1,622

)

 

216

 

Accounts payable

 

 

(3,346

)

 

(1,301

)

Other liabilities

 

 

(9,318

)

 

7,947

 

Net cash provided by operating activities

 

 

78,962

 

 

15,066

 

Investing activities

 

 

 

 

 

Acquisition of property and equipment

 

 

(8,472

)

 

(8,504

)

Equity method investments

 

 

(2,150

)

 

(9,551

)

Business acquisition, net of cash acquired

 

 

 

 

(18,641

)

Proceeds from sale of property and equipment

 

 

 

 

81

 

Redemptions of held-to-maturity investments

 

 

 

 

166,917

 

Purchases of held-to-maturity investments

 

 

 

 

(162,517

)

Redemptions of available-for-sale investments

 

 

130,066

 

 

41,150

 

Purchases of available-for-sale investments

 

 

(125,644

)

 

(59,297

)

Net cash used in investing activities

 

 

(6,200

)

 

(50,362

)

Financing activities

 

 

 

 

 

Tax withholding payment related to net settlement of equity awards

 

 

(1,955

)

 

(1,009

)

Holdback and retention payments for business acquisition

 

 

(1,492

)

 

 

Exercise of stock options

 

 

86

 

 

93

 

Net cash used in financing activities

 

 

(3,361

)

 

(916

)

Net increase (decrease) in cash, cash equivalents, and restricted cash

 

 

69,401

 

 

(36,212

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

255,142

 

 

172,708

 

Cash, cash equivalents and restricted cash at end of period

 

$

324,543

 

$

136,496

 

Supplemental disclosures of cash flow information

 

 

 

 

 

Cash paid, net during the period for:

 

 

 

 

 

Income taxes

 

$

2,364

 

$

518

 

Non-cash activities

 

 

 

 

 

Unrealized loss on available-for-sale investments, net of deferred tax benefit of $2

 

$

56

 

$

 

Change in foreign currency translation adjustments

 

$

75

 

$

67

 

Acquisitions of property and equipment included in accounts payable

 

$

746

 

$

263

 

AeroVironment, Inc.

Reconciliation of non-GAAP Earnings per Diluted Share (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended

 

Three Months

Ended

Nine Months

Ended

 

Nine Months

Ended

 

 

January 30, 2021

 

January 25, 2020

January 30, 2021

 

January 25, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per diluted share

 

$

0.01

 

$

(0.04

)

$

0.51

 

$

0.98

Acquisition-related expenses

 

 

0.11

 

 

0.01

 

 

0.14

 

 

0.03

Amortization of acquired intangible assets

 

 

0.02

 

 

0.02

 

 

0.06

 

 

0.06

HAPSMobile Inc. JV impairment of investment in Loon LLC

 

 

 

 

 

 

0.35

 

 

Earnings (loss) per diluted share as adjusted (Non-GAAP)

 

$

0.14

 

 

(0.01

)

$

1.06

 

$

1.07

Reconciliation of Forecast Earnings per Diluted Share (Unaudited)

 

 

 

 

 

 

Fiscal year ending

 

 

April 30, 2021

Forecast earnings per diluted share

 

$

0.76 – 0.96

Acquisition-related expenses

 

 

0.40

Amortization of acquired intangible assets

 

 

0.23

HAPSMobile Inc. JV impairment of investment in Loon LLC

 

 

0.35

Forecast earnings per diluted share as adjusted (Non-GAAP)

 

$

1.74 – 1.94

Reconciliation of Fiscal Year 2020 Actual, and 2021 and 2022 Forecast Non-GAAP adjusted EBITDA (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Fiscal year ending

 

Fiscal year ending

 

Fiscal year ending

(in millions)

 

April 30, 2020

 

April 30, 2021

 

April 30, 2022

Net income from continuing operations

 

$

41

 

 

$

18 – 23

 

$

35 – 40

Interest (income) expense, net

 

 

(5

)

 

 

1

 

 

5

Provision for income taxes

 

 

6

 

 

 

2

 

 

4

Depreciation and amortization

 

 

10

 

 

 

21

 

 

64

EBITDA (Non-GAAP)

 

 

52

 

 

 

42 – 47

 

 

108 – 113

Equity Method Investment

 

 

6

 

 

 

11

 

 

Deal and integration costs

 

 

1

 

 

 

11

 

 

2

Adjusted EBITDA (Non-GAAP)

 

$

59

 

 

$

64 – 69

 

$

110 – 115

Statement Regarding Non-GAAP Measures

The non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing our results that, when reconciled to the corresponding GAAP measures, help our investors to understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers. In addition, management uses these non-GAAP measures to evaluate our operating and financial performance.

Non-GAAP Earnings per Diluted Share

We exclude the acquisition-related expenses, amortization of acquisition-related intangible assets and one-time non-operating items because we believe this facilitates more consistent comparisons of operating results over time between our newly acquired and existing businesses, and with our peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization will recur in future periods until such intangible assets have been fully amortized.

Adjusted EBITDA (Non-GAAP)

Adjusted EBITDA is defined as net income before interest income, interest expense, income tax expense (benefit) and depreciation and amortization, adjusted for the impact of certain other items, including acquisition-related expenses, purchase accounting adjustments, and equity method investment gains or losses. We present Adjusted EBITDA, which is not a recognized financial measure under U.S. GAAP, because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We believe this facilitates more consistent comparisons of operating results over time between our newly acquired and existing businesses, and with our peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation, intangible asset amortization will recur in future periods until such intangible assets have been fully amortized and that interest and income tax expenses will recur in future periods. In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

For additional media and information, please follow us:

http://www.twitter.com/aerovironment

http://www.facebook.com/aerovironmentinc

https://www.instagram.com/aerovironmentinc/

http://www.youtube.com/user/AeroVironmentInc

https://www.linkedin.com/company/aerovironment

AeroVironment, Inc.

Steven Gitlin

+1 (805) 520-8350

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Defense Technology Aerospace Manufacturing Software Other Defense Hardware

MEDIA:

Logo
Logo
Photo
Photo
AeroVironment’s Portfolio of Unmanned Systems (Graphic: Business Wire)